Circulating progenitor cells in hypertensive subjects: Effectiveness of a treatment with olmesartan in improving cell number and miR profile in addition to expected pharmacological effects.
CD34+ circulating progenitor cells (CD34+CPCs) are a population of multipotent cells which can delay the development of atherosclerosis and cardiovascular disease (CVD) in conditions of increased CV risk. MicroRNAs (miRs) 221 and 222 modulate different genes regulating angiogenesis and inflammation;...
Main Authors: | Giuseppe Mandraffino, Caterina Oriana Aragona, Valentina Cairo, Michele Scuruchi, Alberto Lo Gullo, Angela D'Ascola, Angela Alibrandi, Saverio Loddo, Sebastiano Quartuccio, Carmela Morace, Enricomaria Mormina, Giorgio Basile, Antonino Saitta, Egidio Imbalzano |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5354372?pdf=render |
Similar Items
-
Expression and Change of miRs 145, 221 and 222 in Hypertensive Subjects Treated with Enalapril, Losartan or Olmesartan
by: Giuseppe Mandraffino, et al.
Published: (2021-07-01) -
Endothelial Progenitor Cells for Diagnosis and Prognosis in Cardiovascular Disease
by: Caterina Oriana Aragona, et al.
Published: (2016-01-01) -
Vitamin D Status in Rheumatoid Arthritis: Inflammation, Arterial Stiffness and Circulating Progenitor Cell Number.
by: Alberto Lo Gullo, et al.
Published: (2015-01-01) -
Subcutaneous administration of tocilizumab is effective in myointimal hyperplasia remodelling in refractory Takayasu arteritis
by: A. Lo Gullo, et al.
Published: (2017-12-01) -
Endocan and Circulating Progenitor Cells in Women with Systemic Sclerosis: Association with Inflammation and Pulmonary Hypertension
by: Alberto Lo Gullo, et al.
Published: (2021-05-01)